Defining Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency

Trial Objective

The purpose of this study is to learn more about alpha-1 antitrypsin deficiency (AATD) and augmentation therapy.

AATD is an inherited condition that causes low levels of, or no, alpha-1 antitrypsin (AAT) in the blood. Augmentation therapy is the use of alpha-1 antitrypsin protein (AAT) from the blood plasma of healthy human donors to augment (increase) the alpha-1 levels circulating in the blood and lungs of AATD patients diagnosed with emphysema. 

If you agree to take part in this study, it will require up to 2 visits over a 6 month period.

  • Blood draw

  • Bronchoscopy


This trial is active and currently recruiting.

How to Participate

For more information, call 303.398.1699 or complete the form below. 

Who Can Participate

Qualifications include:

  • Adults 18 years of age or older who are Alpha-1 phenotype ZZ
  • Not on augmentation therapy




Any Gender

Trial Location

National Jewish Main Campus, Denver, CO



Trial Sponsors

National Institutes of Health

Estimated Time Commitment

2 visits (30 mins. long)

Principal Investigators

  • image description
    Nabeel Hamzeh, MD, FCCP

Request More Information